129 related articles for article (PubMed ID: 23756368)
1. Synthesis and structure-activity relationship of 2-arylamino-4-aryl-pyrimidines as potent PAK1 inhibitors.
Xu Y; Foulks JM; Clifford A; Brenning B; Lai S; Luo B; Parnell KM; Merx S; McCullar MV; Kanner SB; Ho KK
Bioorg Med Chem Lett; 2013 Jul; 23(14):4072-5. PubMed ID: 23756368
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of 1H-pyrazolo [3,4-d]pyrimidine derivatives as PAK1 inhibitors that trigger apoptosis, ER stress and anti-migration effect in MDA-MB-231 cells.
Zhang J; Zou L; Tang P; Pan D; He Z; Yao D
Eur J Med Chem; 2020 May; 194():112220. PubMed ID: 32222676
[TBL] [Abstract][Full Text] [Related]
3. 4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors.
Zhang N; Wu B; Boschelli DH; Golas JM; Boschelli F
Bioorg Med Chem Lett; 2009 Sep; 19(17):5071-4. PubMed ID: 19632113
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of 1-aryl-5-anilinoindazoles as c-Jun N-terminal kinase inhibitors.
Jiang R; Frackowiak B; Shin Y; Song X; Chen W; Lin L; Cameron MD; Duckett DR; Kamenecka TM
Bioorg Med Chem Lett; 2013 May; 23(9):2683-7. PubMed ID: 23518277
[TBL] [Abstract][Full Text] [Related]
5. The design, synthesis, and biological evaluation of PIM kinase inhibitors.
Tsuhako AL; Brown DS; Koltun ES; Aay N; Arcalas A; Chan V; Du H; Engst S; Franzini M; Galan A; Huang P; Johnston S; Kane B; Kim MH; Laird AD; Lin R; Mock L; Ngan I; Pack M; Stott G; Stout TJ; Yu P; Zaharia C; Zhang W; Zhou P; Nuss JM; Kearney PC; Xu W
Bioorg Med Chem Lett; 2012 Jun; 22(11):3732-8. PubMed ID: 22542012
[TBL] [Abstract][Full Text] [Related]
6. 4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies.
Puig de la Bellacasa R; Roué G; Balsas P; Pérez-Galán P; Teixidó J; Colomer D; Borrell JI
Eur J Med Chem; 2014 Oct; 86():664-75. PubMed ID: 25222877
[TBL] [Abstract][Full Text] [Related]
7. The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer.
Lippa B; Kauffman GS; Arcari J; Kwan T; Chen J; Hungerford W; Bhattacharya S; Zhao X; Williams C; Xiao J; Pustilnik L; Su C; Moyer JD; Ma L; Campbell M; Steyn S
Bioorg Med Chem Lett; 2007 Jun; 17(11):3081-6. PubMed ID: 17398092
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors.
Waterson AG; Petrov KG; Hornberger KR; Hubbard RD; Sammond DM; Smith SC; Dickson HD; Caferro TR; Hinkle KW; Stevens KL; Dickerson SH; Rusnak DW; Spehar GM; Wood ER; Griffin RJ; Uehling DE
Bioorg Med Chem Lett; 2009 Mar; 19(5):1332-6. PubMed ID: 19208477
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of novel tetrahydrothieno [2,3-c]pyridine substitued benzoyl thiourea derivatives as PAK1 inhibitors in triple negative breast cancer.
Yao D; Huang J; Wang J; He Z; Zhang J
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1524-1538. PubMed ID: 32752894
[TBL] [Abstract][Full Text] [Related]
10. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.
Licciulli S; Maksimoska J; Zhou C; Troutman S; Kota S; Liu Q; Duron S; Campbell D; Chernoff J; Field J; Marmorstein R; Kissil JL
J Biol Chem; 2013 Oct; 288(40):29105-14. PubMed ID: 23960073
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of novel 6-aryl substituted 4-anilinequinazoline derivatives as potential PI3Kδ inhibitors.
Xin M; Hei YY; Zhang H; Shen Y; Zhang SQ
Bioorg Med Chem Lett; 2017 May; 27(9):1972-1977. PubMed ID: 28325601
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of 2-indolinone derivatives as PAK1 inhibitors in MDA-MB-231 cells.
Yao D; Ruhan A; Jiang J; Huang J; Wang J; Han W
Bioorg Med Chem Lett; 2020 Sep; 30(17):127355. PubMed ID: 32738980
[TBL] [Abstract][Full Text] [Related]
13. Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window.
Rudolph J; Murray LJ; Ndubaku CO; O'Brien T; Blackwood E; Wang W; Aliagas I; Gazzard L; Crawford JJ; Drobnick J; Lee W; Zhao X; Hoeflich KP; Favor DA; Dong P; Zhang H; Heise CE; Oh A; Ong CC; La H; Chakravarty P; Chan C; Jakubiak D; Epler J; Ramaswamy S; Vega R; Cain G; Diaz D; Zhong Y
J Med Chem; 2016 Jun; 59(11):5520-41. PubMed ID: 27167326
[TBL] [Abstract][Full Text] [Related]
14. Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors.
Pecchi S; Renhowe PA; Taylor C; Kaufman S; Merritt H; Wiesmann M; Shoemaker KR; Knapp MS; Ornelas E; Hendrickson TF; Fantl W; Voliva CF
Bioorg Med Chem Lett; 2010 Dec; 20(23):6895-8. PubMed ID: 21035331
[TBL] [Abstract][Full Text] [Related]
15. The design, synthesis and biological evaluation of 7-alkoxy-4-heteroarylamino-3-cyanoquinolines as dual inhibitors of c-Src and iNOS.
Cao X; You QD; Li ZY; Liu XR; Xu D; Guo QL; Shang J; Chern JW; Chen ML
Bioorg Med Chem Lett; 2008 Dec; 18(23):6206-9. PubMed ID: 18930653
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of the tyrosine kinase EphB4. Part 4: Discovery and optimization of a benzylic alcohol series.
Barlaam B; Ducray R; Lambert-van der Brempt C; Plé P; Bardelle C; Brooks N; Coleman T; Cross D; Kettle JG; Read J
Bioorg Med Chem Lett; 2011 Apr; 21(8):2207-11. PubMed ID: 21441027
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.
Cheng H; Hoffman JE; Le PT; Pairish M; Kania R; Farrell W; Bagrodia S; Yuan J; Sun S; Zhang E; Xiang C; Dalvie D; Rahavendran SV
Bioorg Med Chem Lett; 2013 May; 23(9):2787-92. PubMed ID: 23506825
[TBL] [Abstract][Full Text] [Related]
18. Small molecules that allosterically inhibit p21-activated kinase activity by binding to the regulatory p21-binding domain.
Kim DJ; Choi CK; Lee CS; Park MH; Tian X; Kim ND; Lee KI; Choi JK; Ahn JH; Shin EY; Shin I; Kim EG
Exp Mol Med; 2016 Apr; 48(4):e229. PubMed ID: 27126178
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kα and mTOR.
Le PT; Cheng H; Ninkovic S; Plewe M; Huang X; Wang H; Bagrodia S; Sun S; Knighton DR; LaFleur Rogers CM; Pannifer A; Greasley S; Dalvie D; Zhang E
Bioorg Med Chem Lett; 2012 Aug; 22(15):5098-103. PubMed ID: 22749419
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors.
Zhao C; Tovar C; Yin X; Xu Q; Todorov IT; Vassilev LT; Chen L
Bioorg Med Chem Lett; 2009 Jan; 19(2):319-23. PubMed ID: 19071019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
